Overview

* Travere Q3 2025 total revenue rose to $164.9 mln, driven by FILSPARI sales growth

* FILSPARI U.S. net product sales grew 155% yr/yr to $90.9 mln in Q3 2025

* Travere achieved $25.7 mln net income in Q3 2025, reversing a loss from prior year

Outlook

* Travere expects FDA approval for FILSPARI in FSGS by January 2026

* Travere aims to restart HARMONY Study of pegtibatinase in 2026

Result Drivers

* FILSPARI SALES GROWTH - FILSPARI U.S. net product sales increased 155% yr/yr to $90.9 mln, driven by continued uptake among prescribers

* MARKET ACCESS MILESTONE - $40 mln market access milestone from CSL Vifor recognized in Q3 2025, enhancing financial results

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $113.15

Product mln

Sales

Q3 EPS $0.28

Q3 Net $25.70

Income mln

Q3 $139.92

Operatin mln

g

Expenses

Q3 $24.93

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Travere Therapeutics Inc ( TVTX ) is $35.00, about 14.3% above its October 29 closing price of $29.98

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)